RVP Narrows Losses to $10.6M on Strong Sales, Faces Gross Profit Headwinds

TL;DR

**RVP's sales are up, but a gross loss and heavy reliance on Chinese manufacturing make this a risky bet for a turnaround.**

AI Summary

Retractable Technologies, Inc. (RVP) reported a net loss of $10,588,187 for the six months ended June 30, 2025, a significant improvement from the $13,735,256 net loss in the comparable 2024 period. Sales, net, increased to $18,740,906 for the first six months of 2025, up from $13,628,727 in the prior year, representing a 37.5% increase. Despite the sales growth, the company recorded a gross loss of $109,001 for the six months ended June 30, 2025, compared to a gross profit of $1,481,005 in the same period of 2024, primarily due to a substantial increase in cost of manufactured product and royalty expense. Operating expenses decreased slightly to $9,698,590 from $10,229,948 year-over-year. The company recognized $1,900,000 in litigation proceeds in the first six months of 2025, which was not present in 2024. Cash and cash equivalents decreased to $3,044,986 as of June 30, 2025, from $4,235,388 at December 31, 2024, with net cash used in operating activities totaling $5,209,566. A notable risk is the company's reliance on Chinese manufacturers for 62% of its products in the first six months of 2025.

Why It Matters

For investors, RVP's ability to significantly narrow its net loss to $10.6 million while boosting sales by 37.5% is a mixed signal, indicating revenue growth but persistent profitability challenges, particularly with the shift from gross profit to gross loss. The reliance on a few significant customers (55% of net sales) and Chinese manufacturers (62% of products) introduces concentration risk, which could impact future stability and competitive positioning. Employees might face continued pressure if the company struggles to achieve consistent profitability, while customers could see potential supply chain vulnerabilities if manufacturing dependencies are disrupted. The broader medical device market will watch if RVP can leverage its sales growth into sustainable positive earnings amidst these operational hurdles.

Risk Assessment

Risk Level: high — The company reported a gross loss of $109,001 for the six months ended June 30, 2025, a significant deterioration from a gross profit of $1,481,005 in the prior year, indicating fundamental profitability issues. Furthermore, RVP obtained 62% of its products from Chinese manufacturers in the first six months of 2025, creating a substantial concentration risk in its supply chain.

Analyst Insight

Investors should exercise extreme caution and consider RVP a speculative investment due to its persistent net losses and negative gross profit. Await clear evidence of sustained positive gross margins and diversification of manufacturing before considering a long position.

Financial Highlights

debt To Equity

0.92

revenue

$18,740,906

operating Margin

-52.3%

total Assets

$147,090,406

total Debt

$724,702

net Income

$(10,588,187)

eps

$(0.36)

gross Margin

-0.6%

cash Position

$3,044,986

revenue Growth

+37.5%

Revenue Breakdown

Key Numbers

• $18,740,906 — Sales, net (Six Months Ended June 30, 2025) (Increased from $13,628,727 in 2024, a 37.5% increase.)
• $(10,588,187) — Net loss (Six Months Ended June 30, 2025) (Improved from $(13,735,256) in 2024.)
• $(109,001) — Gross profit (loss) (Six Months Ended June 30, 2025) (Deteriorated from $1,481,005 in 2024.)
• $3,044,986 — Cash and cash equivalents (June 30, 2025) (Decreased from $4,235,388 at December 31, 2024.)
• $1,900,000 — Litigation proceeds (Six Months Ended June 30, 2025) (New income source not present in 2024.)
• 62% — Products from Chinese manufacturers (Six Months Ended June 30, 2025) (Represents a significant concentration risk.)
• 55.0% — Percentage of net sales to significant customers (Six Months Ended June 30, 2025) (Indicates customer concentration risk.)
• $(0.36) — Basic loss per share (Six Months Ended June 30, 2025) (Improved from $(0.46) in 2024.)

Key Players & Entities

• RETRACTABLE TECHNOLOGIES INC (company) — registrant
• Texas (person) — state of incorporation
• Little Elm, Texas (person) — location of manufacturing and administrative facilities
• VanishPoint (company) — product line
• EasyPoint (company) — product line
• China (person) — source of manufacturing
• NYSE American (regulator) — exchange where common stock is registered
• SEC (regulator) — filing authority

FAQ

Risk Factors

• Manufacturing Concentration in China [high — operational]: The company relies on Chinese manufacturers for 62% of its products. This concentration exposes RVP to risks related to geopolitical tensions, supply chain disruptions, trade policies, and quality control issues originating from China.
• Negative Gross Profit and Cash Burn [high — financial]: For the six months ended June 30, 2025, RVP reported a gross loss of $109,001, a significant deterioration from a gross profit of $1,481,005 in the prior year. This, coupled with net cash used in operating activities of $5,209,566, indicates ongoing financial pressure.
• Declining Cash Position [medium — financial]: Cash and cash equivalents decreased from $4,235,388 at December 31, 2024, to $3,044,986 as of June 30, 2025. This reduction in liquidity, alongside negative operating cash flow, warrants close monitoring.
• Customer Concentration [medium — financial]: The company generates 55.0% of its net sales from significant customers. A loss of one or more of these key customers could have a material adverse effect on RVP's financial condition and results of operations.
• Increased Cost of Goods Sold [medium — operational]: The cost of manufactured product and royalty expense increased substantially, leading to a gross loss. This rise in costs, despite higher sales, suggests potential issues with production efficiency, raw material costs, or unfavorable royalty terms.

Industry Context

Retractable Technologies, Inc. operates in the medical device sector, specifically focusing on safety-engineered sharps disposal systems. The industry is characterized by stringent regulatory requirements, a need for continuous innovation to enhance safety and usability, and competition from both established players and emerging companies. Trends include increasing demand for infection control products and a growing emphasis on clinician and patient safety.

Regulatory Implications

As a medical device manufacturer, RVP is subject to regulations from bodies like the FDA. Compliance with manufacturing standards (e.g., ISO 13485) and product safety regulations is critical. Any failure to comply could result in product recalls, fines, or market access restrictions, impacting financial performance and operational continuity.

What Investors Should Do

1. Monitor cost of goods sold and gross margin trends closely.
2. Evaluate the sustainability of sales growth against cost pressures.
3. Assess the impact of litigation proceeds on financial stability.
4. Analyze supply chain diversification efforts.
5. Scrutinize cash flow generation and liquidity management.

Key Dates

• 2025-06-30: End of Second Quarter 2025 — Reporting period for the condensed financial statements, showing increased sales but a gross loss and reduced cash.
• 2024-06-30: End of Second Quarter 2024 — Comparative period for financial results, showing a gross profit and higher cash balance.
• 2024-12-31: End of Fiscal Year 2024 — Balance sheet comparison point for cash and cash equivalents.

Glossary

Sales, net

The total revenue generated from sales after deducting any returns, allowances, and discounts. (Indicates the company's top-line performance and market demand for its products.)

Gross profit (loss)

Revenue minus the cost of goods sold (including manufactured product costs and royalties). A negative figure indicates a loss. (Measures the profitability of the company's core product sales before considering operating expenses.)

Operating expenses

Costs incurred in the normal course of business, excluding cost of sales. Includes sales and marketing, R&D, and general and administrative expenses. (Reflects the company's investment in growth, innovation, and day-to-day operations.)

Loss from operations

The result of subtracting total operating expenses and cost of sales from net sales. It represents the profit or loss from core business activities. (Shows the profitability of the company's primary business operations before accounting for other income or expenses.)

Cash and cash equivalents

Highly liquid investments with maturities of three months or less at the time of purchase. Represents readily available funds. (Indicates the company's short-term liquidity and ability to meet immediate financial obligations.)

Net cash used in operating activities

The net outflow of cash resulting from the normal day-to-day business operations of the company. (Shows whether the company's core business is generating or consuming cash.)

Retained earnings

The cumulative amount of net income that a company has retained over time, rather than distributing to shareholders as dividends. (Reflects the company's historical profitability and its ability to reinvest earnings back into the business.)

Year-Over-Year Comparison

Compared to the prior year's six-month period, Retractable Technologies, Inc. (RVP) has seen a significant increase in net sales, up 37.5% to $18,740,906. However, this top-line growth has been overshadowed by a severe deterioration in gross profit, which turned into a loss of $109,001 from a profit of $1,481,005. This is attributed to higher costs of manufactured product and royalty expenses. While operating expenses saw a slight decrease, the company's net loss widened slightly to $10,588,187, though the loss per share improved due to a higher share count. A new risk factor is the company's increased reliance on Chinese manufacturers, now at 62% of products.

Filing Documents

• tmb-20250630x10q.htm (10-Q) — 1396KB
• tmb-20250630xex31d1.htm (EX-31.1) — 14KB
• tmb-20250630xex31d2.htm (EX-31.2) — 14KB
• tmb-20250630xex32.htm (EX-32) — 8KB
• 0001558370-25-011539.txt ( ) — 6623KB
• tmb-20250630.xsd (EX-101.SCH) — 38KB
• tmb-20250630_cal.xml (EX-101.CAL) — 47KB
• tmb-20250630_def.xml (EX-101.DEF) — 140KB
• tmb-20250630_lab.xml (EX-101.LAB) — 324KB
• tmb-20250630_pre.xml (EX-101.PRE) — 231KB
• tmb-20250630x10q_htm.xml (XML) — 1506KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements 1 CONDENSED BALANCE SHEETS 1 CONDENSED STATEMENTS OF OPERATIONS 2 CONDENSED STATEMENTS OF CASH FLOWS 3 CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY 4 NOTES TO CONDENSED FINANCIAL STATEMENTS 5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 16 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 22 Item 4.

Controls and Procedures

Controls and Procedures 22

—OTHER INFORMATION

PART II—OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 23 Item 1A.

Risk Factors

Risk Factors 23 Item 5. Other Information 23 Item 6. Exhibits 23

SIGNATURES

SIGNATURES 24 Table of Contents

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. RETRACTABLE TECHNOLOGIES, INC. CONDENSED BALANCE SHEETS (unaudited) June 30, 2025 December 31, 2024 ASSETS Current assets: Cash and cash equivalents $ 3,044,986 $ 4,235,388 Accounts receivable, net 8,085,890 7,786,697 Investments in debt and equity securities, at fair value 30,009,302 40,328,308 Inventories 20,449,860 19,189,753 Income taxes receivable 662,429 978,851 Other current assets 744,351 753,062 Total current assets 62,996,818 73,272,059 Property, plant, and equipment, net 84,012,319 87,348,518 Other assets 81,269 103,625 Total assets $ 147,090,406 $ 160,724,202 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 4,060,355 $ 4,290,588 Current portion of long-term debt 349,962 332,480 Accrued compensation 1,029,652 1,073,357 Dividends payable 1,417,437 1,417,437 Accrued royalties to shareholder 831,209 789,358 Other accrued liabilities 1,294,852 873,254 Income taxes payable 3,628 4,442 Total current liabilities 8,987,095 8,780,916 Other long-term liabilities 60,918,499 63,872,553 Long-term debt, net of current maturities 717,530 900,042 Total liabilities 70,623,124 73,553,511 Commitments and contingencies – see Note 8 Stockholders' equity: Preferred stock, $ 1 par value: Class B; authorized: 5,000,000 shares Series II, Class B 156,200 156,200 Series III, Class B 74,245 74,245 Common Stock, no par value — — Additional paid-in capital 73,160,333 73,160,333 Retained earnings 15,965,182 26,668,591 Common stock in treasury – at cost ( 12,888,678 ) ( 12,888,678 ) Total stockholders' equity 76,467,282 87,170,691 Total liabilities and stockholders' equity $ 147,090,406 $ 160,724,202 See accompanying notes to condensed unaudited financial statements 1 Table of Contents RETRACTABLE TECHNOLOGIES, INC. CONDENSED STATEMENTS OF OPERATIONS

View Full Filing

View this 10-Q filing on SEC EDGAR